Blog | Understanding Adaptive Clinical Trials - NFCR


Understanding Adaptive Clinical Trials

Testing new treatments is key to successfully treating cancer. Unfortunately, the current model for conducting clinical trials — evaluating the effectiveness of therapies on human subjects — is inefficient, expensive and suffers from high failure rates. To overcome these challenges, the practice of adaptive trials is emerging and has become one of the most promising advancements in cancer research today.

Challenges with traditional clinical trials

Currently, it takes approximately $2.5 billion dollars, 10+ years and thousands of patient volunteers to bring one drug to market.[i] Despite this high cost, over half of phase III oncology trials have negative results or fail to complete. In addition, traditional trials cannot be modified once they begin. Patients get only one opportunity and receive only one treatment.

Adaptive trials literally adapt as evidence accumulates

Adaptive trials do not require years of follow-up to determine whether a new experimental treatment is beneficial. They test multiple treatments and combinations of treatments on patients in parallel and are designed to be continuously updated as researchers use what they learn from each patient to make real-time adjustments as the trial proceeds.

They are flexible by design so adjustments can be made in terms of dosage, subject population or sample size as needed.

In an adaptive trial, if one treatment regimen seems to be more successful, researchers can increase the number of participants receiving that treatment. This is especially important for patients with aggressive cancers as life expectancies are too short for traditional trial timetables. With adaptive trials, ineffective treatments can be shut down early, and new treatments can be initiated quickly enabling patients to receive the most promising treatments faster.

In a latest article published on Science Magazine: “Congress and FDA nominee heap love on ‘adaptive trials”, GBM AGILE is featured as one of the ongoing clinical trials using this new adaptive trial design.

GBM AGILE revolutionizes brain cancer trials

Glioblastoma multiforme (also known as GBM) is the deadliest brain cancer and is widely regarded as incurable and universally fatal, killing 95% of patients within five years of diagnosis. To combat this deadly disease, NFCR is part of a robust, international coalition working on innovative ways to defeat GBM utilizing adaptive trials known as GBM AGILE.

Led by the best and brightest cancer researchers, GBM AGILE is a revolutionary global collaboration to test and develop new brain cancer treatments. Its personalized approach will allow us to accelerate the discovery of targeted treatments for individual patients. This global coalition has attracted over 150 participants from more than 40 leading cancer institutions across three continents. This revolutionary approach accelerates research for curing the aggressive form of brain cancer GBM and will serve as a new clinical research model for combating other cancers as well.

In addition to GBM AGILE, there are other adaptive trials underway for certain cancers and tumor types, with more coming soon.  Other trials include:

  • I-SPY TRIAL is an adaptive clinical trial for women with newly diagnosed, locally advanced breast cancer.
  • Lung-MAP is a large adaptive clinical trial testing several new treatments for patients who have advanced stage squamous cell lung cancer.
  • Precision Promise is the first large-scale precision medicine adaptive trial for patients with pancreatic cancer.

While adaptive trial features are not yet commonplace, Congress and the FDA are focused on accelerating their development to benefit patients.



  1. REPLY
    Gina Henrie says

    I’ve been looking into understanding clinical research but I”m not sure where to start. I like what you said that that testing new treatment is key to successfully treat cancer. This is good information to know, thanks for sharing!

  2. REPLY
    Clinical Trails says

    Thank you for the information you provided, I was wandering for some articles under clinical trials and here alas! Ive found many. I enjoy being pharmacologist when I get information very precisely.

  3. REPLY
    Pubrica says

    Hai…you have posted great article, it really helpful to us.. I will refer this page to my friends; I hope they will like to read

  4. REPLY
    Devansh Karnani says

    We can gain a firm knowledge and understanding of the Clinical Research by this blog. I look forward to more updates and will be returning.

  5. REPLY
    Flora says

    Thank you for sharing this information with us. Really helpful and informative. looking forward to read more such articles from you.

  6. REPLY
    Online Clinical Research Courses says

    Thank you for sharing this article.

  7. REPLY
    ClinicalResearch says

    thank you for your efforts towards the blog. we will refer to others also.

  8. REPLY
    ProCTH says

    Great content!! Keep sharing informative articles like these.

  9. REPLY
    Veena Dimak says

    Thanks for crafting this beautiful information about Clinical Trials. This is the best blog I have ever read. I’m going to make sure that I will share.

  10. REPLY
    ClinicalResearch says

    It was a very good article on clinical Trial. Can you please suggest few other similar articles that I can go through and expand my understanding on the same.

  11. REPLY
    raveena aher says

    thank you

Post a comment